» Articles » PMID: 3260522

A Ki-1 (CD30)-positive Human Cell Line (Karpas 299) Established from a High-grade Non-Hodgkin's Lymphoma, Showing a 2;5 Translocation and Rearrangement of the T-cell Receptor Beta-chain Gene

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1988 Jul 1
PMID 3260522
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

We describe the characterization of a new human cell line, Karpas 299 (K299), established from blast cells in the peripheral blood of a 25-year-old white man. His illness, which began with enlarged occipital and axillary nodes and weight loss, ended after 7 months with generalized lymphadenopathy, pleural effusion, and bone marrow involvement. A lymph node biopsy showed a large cell lymphoma mainly sinusoidal in distribution. The blast cells with pleomorphic nuclei resembled primitive histiocytes. The cells, which expressed the T-cell-associated markers CD4 and CD5, were positive for HLA-DR, epithelial membrane antigen, and CD30 (Ki-1 antigen). The karyotype was aneuploid and included a translocation 2;5. The site of translocation on chromosome 5 (at 5q35.1) is in the region of the locus of the c-fms oncogene (receptor of the monocyte-macrophage colony-stimulating factor MCSF or CSF-1). The cell line Karpas 299 has the same karyotype and pattern of antigen expression as the patient's cells. Northern blot analysis of RNA showed an active rearrangement of the T-cell receptor beta-chain gene. This is to our knowledge the first Ki-1 antigen-positive line to be established from a case of non-Hodgkin's lymphoma.

Citing Articles

Regulation of CXCR4 function by S1P through heteromerization.

Kim H, Jeong J, Huh W Cell Commun Signal. 2025; 23(1):111.

PMID: 40012038 PMC: 11863771. DOI: 10.1186/s12964-025-02099-x.


Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule.

Akiba H, Ise T, Satoh R, Abe Y, Tsumoto K, Ohno H Antib Ther. 2025; 8(1):56-67.

PMID: 39958564 PMC: 11826918. DOI: 10.1093/abt/tbaf002.


Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer.

Sun Y, Ma L, Zhang X, Wang Z Onco Targets Ther. 2024; 17:1095-1115.

PMID: 39583247 PMC: 11585992. DOI: 10.2147/OTT.S487870.


Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.

Sungwan P, Panaampon J, Kariya R, Kamio S, Nakagawa R, Hirozane T Hum Cell. 2024; 37(4):1215-1225.

PMID: 38755432 DOI: 10.1007/s13577-024-01077-8.


The Opposite Functions of CD30 Ligand Isoforms.

Printsev I, Alalli E, Bilsborough J Curr Issues Mol Biol. 2024; 46(3):2741-2756.

PMID: 38534788 PMC: 10969620. DOI: 10.3390/cimb46030172.